English
简体中文
Total: £ 56.28
Published Date: 2025-08-08 | Pages: 100 | Tables: 97 | Medical Care
The global Leukemia Molecular Diagnostics market size was US$ 2115 million in 2024 and is forecast to a readjusted size of US$ 4175 million by 2031 with a CAGR of 10.4% during the forecast period 2025-2031.
Molecular diagnosis of leukemia is a method of diagnosing and classifying leukemia by detecting specific gene mutations, chromosomal abnormalities or other molecular markers in leukemia patients. This diagnostic technology uses advanced molecular biology tools such as PCR (polymerase chain reaction), gene sequencing and fluorescence in situ hybridization (FISH) to identify molecular features in leukemia cells. Molecular diagnosis of leukemia not only helps to diagnose the disease, but also can accurately classify leukemia subtypes, providing an important basis for the formulation of individualized treatment plans. This precise diagnostic method helps to assess the patient's prognosis, monitor the effectiveness of treatment, and detect the risk of recurrence at an early stage. It is an indispensable tool in modern leukemia management.
The increasing adoption of personalized medicine is a key driver for the leukemia molecular diagnostics market. Advances in molecular diagnostic technologies, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), enable precise genetic profiling of leukemia, leading to more targeted and effective treatment plans. This personalized approach not only improves patient outcomes but also boosts demand for molecular diagnostics in leukemia management.
One of the main challenges in the leukemia molecular diagnostics market is the high cost associated with advanced diagnostic tools and testing procedures. These technologies often require significant investment in equipment, skilled personnel, and infrastructure, which can limit accessibility in low-resource settings, reducing the potential reach of molecular diagnostics in leukemia care.
The global Leukemia Molecular Diagnostics market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Ruiang Gene
Zhishan Bio
Zhijiang Bio
Jinpujia Medical
Merle Bio
Herui Gene
Aicon Bio
Annuouda
Beijing Wantai
Haixi Bio
Qiagen
Abbott
Kanglu Biotechnology
Guangzhou Anbiping
By Type: (Dominant Segment vs High-Margin Innovation)
PCR
FISH
DNA Sequencing
Gene Chip
By Application: (Core Demand Driver vs Emerging Opportunity)
Clinical Diagnosis
Drug Screening
Research
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Ruiang Gene in Europe)
- Emerging Product Trends: PCR adoption vs. FISH premiumization
- Demand-Side Dynamics: Clinical Diagnosis growth in China vs. Drug Screening potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
(Additional regions can be customized based on client needs.)
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Leukemia Molecular Diagnostics market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., FISH in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Drug Screening in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Leukemia Molecular Diagnostics value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 PCR
1.2.3 FISH
1.2.4 DNA Sequencing
1.2.5 Gene Chip
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Clinical Diagnosis
1.3.3 Drug Screening
1.3.4 Research
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Leukemia Molecular Diagnostics Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Leukemia Molecular Diagnostics Revenue Market Share by Region (2020-2025)
2.4 Global Leukemia Molecular Diagnostics Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Leukemia Molecular Diagnostics Market Size and Prospective (2020-2031)
2.5.2 Europe Leukemia Molecular Diagnostics Market Size and Prospective (2020-2031)
2.5.3 China Leukemia Molecular Diagnostics Market Size and Prospective (2020-2031)
2.5.4 Japan Leukemia Molecular Diagnostics Market Size and Prospective (2020-2031)
2.5.5 Southeast Asia Leukemia Molecular Diagnostics Market Size and Prospective (2020-2031)
2.5.6 India Leukemia Molecular Diagnostics Market Size and Prospective (2020-2031)
2.5.7 Central & South America Leukemia Molecular Diagnostics Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Leukemia Molecular Diagnostics Historic Market Size by Type (2020-2025)
3.2 Global Leukemia Molecular Diagnostics Forecasted Market Size by Type (2026-2031)
3.3 Different Types Leukemia Molecular Diagnostics Representative Players
4 Breakdown Data by Application
4.1 Global Leukemia Molecular Diagnostics Historic Market Size by Application (2020-2025)
4.2 Global Leukemia Molecular Diagnostics Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Leukemia Molecular Diagnostics Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Leukemia Molecular Diagnostics Players by Revenue (2020-2025)
5.1.2 Global Leukemia Molecular Diagnostics Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Leukemia Molecular Diagnostics Revenue
5.4 Global Leukemia Molecular Diagnostics Market Concentration Analysis
5.4.1 Global Leukemia Molecular Diagnostics Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Leukemia Molecular Diagnostics Revenue in 2024
5.5 Global Key Players of Leukemia Molecular Diagnostics Head office and Area Served
5.6 Global Key Players of Leukemia Molecular Diagnostics, Product and Application
5.7 Global Key Players of Leukemia Molecular Diagnostics, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Leukemia Molecular Diagnostics Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Leukemia Molecular Diagnostics Market Size by Type (2020-2025)
6.1.2.2 North America Leukemia Molecular Diagnostics Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Leukemia Molecular Diagnostics Market Size by Application (2020-2025)
6.1.3.2 North America Leukemia Molecular Diagnostics Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Leukemia Molecular Diagnostics Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Leukemia Molecular Diagnostics Market Size by Type (2020-2025)
6.2.2.2 Europe Leukemia Molecular Diagnostics Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Leukemia Molecular Diagnostics Market Size by Application (2020-2025)
6.2.3.2 Europe Leukemia Molecular Diagnostics Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments and Downstream
6.3.1 China Leukemia Molecular Diagnostics Revenue by Company (2020-2025)
6.3.2 China Market Size by Type
6.3.2.1 China Leukemia Molecular Diagnostics Market Size by Type (2020-2025)
6.3.2.2 China Leukemia Molecular Diagnostics Market Share by Type (2020-2025)
6.3.3 China Market Size by Application
6.3.3.1 China Leukemia Molecular Diagnostics Market Size by Application (2020-2025)
6.3.3.2 China Leukemia Molecular Diagnostics Market Share by Application (2020-2025)
6.3.4 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments and Downstream
6.4.1 Japan Leukemia Molecular Diagnostics Revenue by Company (2020-2025)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan Leukemia Molecular Diagnostics Market Size by Type (2020-2025)
6.4.2.2 Japan Leukemia Molecular Diagnostics Market Share by Type (2020-2025)
6.4.3 Japan Market Size by Application
6.4.3.1 Japan Leukemia Molecular Diagnostics Market Size by Application (2020-2025)
6.4.3.2 Japan Leukemia Molecular Diagnostics Market Share by Application (2020-2025)
6.4.4 Japan Market Trend and Opportunities
6.5 Southeast Asia Market: Players, Segments and Downstream
6.5.1 Southeast Asia Leukemia Molecular Diagnostics Revenue by Company (2020-2025)
6.5.2 Southeast Asia Market Size by Type
6.5.2.1 Southeast Asia Leukemia Molecular Diagnostics Market Size by Type (2020-2025)
6.5.2.2 Southeast Asia Leukemia Molecular Diagnostics Market Share by Type (2020-2025)
6.5.3 Southeast Asia Market Size by Application
6.5.3.1 Southeast Asia Leukemia Molecular Diagnostics Market Size by Application (2020-2025)
6.5.3.2 Southeast Asia Leukemia Molecular Diagnostics Market Share by Application (2020-2025)
6.5.4 Southeast Asia Market Trend and Opportunities
6.6 India Market: Players, Segments and Downstream
6.6.1 India Leukemia Molecular Diagnostics Revenue by Company (2020-2025)
6.6.2 India Market Size by Type
6.6.2.1 India Leukemia Molecular Diagnostics Market Size by Type (2020-2025)
6.6.2.2 India Leukemia Molecular Diagnostics Market Share by Type (2020-2025)
6.6.3 India Market Size by Application
6.6.3.1 India Leukemia Molecular Diagnostics Market Size by Application (2020-2025)
6.6.3.2 India Leukemia Molecular Diagnostics Market Share by Application (2020-2025)
6.6.4 India Market Trend and Opportunities
7 Key Players Profiles
7.1 Ruiang Gene
7.1.1 Ruiang Gene Company Details
7.1.2 Ruiang Gene Business Overview
7.1.3 Ruiang Gene Leukemia Molecular Diagnostics Introduction
7.1.4 Ruiang Gene Revenue in Leukemia Molecular Diagnostics Business (2020-2025)
7.1.5 Ruiang Gene Recent Development
7.2 Zhishan Bio
7.2.1 Zhishan Bio Company Details
7.2.2 Zhishan Bio Business Overview
7.2.3 Zhishan Bio Leukemia Molecular Diagnostics Introduction
7.2.4 Zhishan Bio Revenue in Leukemia Molecular Diagnostics Business (2020-2025)
7.2.5 Zhishan Bio Recent Development
7.3 Zhijiang Bio
7.3.1 Zhijiang Bio Company Details
7.3.2 Zhijiang Bio Business Overview
7.3.3 Zhijiang Bio Leukemia Molecular Diagnostics Introduction
7.3.4 Zhijiang Bio Revenue in Leukemia Molecular Diagnostics Business (2020-2025)
7.3.5 Zhijiang Bio Recent Development
7.4 Jinpujia Medical
7.4.1 Jinpujia Medical Company Details
7.4.2 Jinpujia Medical Business Overview
7.4.3 Jinpujia Medical Leukemia Molecular Diagnostics Introduction
7.4.4 Jinpujia Medical Revenue in Leukemia Molecular Diagnostics Business (2020-2025)
7.4.5 Jinpujia Medical Recent Development
7.5 Merle Bio
7.5.1 Merle Bio Company Details
7.5.2 Merle Bio Business Overview
7.5.3 Merle Bio Leukemia Molecular Diagnostics Introduction
7.5.4 Merle Bio Revenue in Leukemia Molecular Diagnostics Business (2020-2025)
7.5.5 Merle Bio Recent Development
7.6 Herui Gene
7.6.1 Herui Gene Company Details
7.6.2 Herui Gene Business Overview
7.6.3 Herui Gene Leukemia Molecular Diagnostics Introduction
7.6.4 Herui Gene Revenue in Leukemia Molecular Diagnostics Business (2020-2025)
7.6.5 Herui Gene Recent Development
7.7 Aicon Bio
7.7.1 Aicon Bio Company Details
7.7.2 Aicon Bio Business Overview
7.7.3 Aicon Bio Leukemia Molecular Diagnostics Introduction
7.7.4 Aicon Bio Revenue in Leukemia Molecular Diagnostics Business (2020-2025)
7.7.5 Aicon Bio Recent Development
7.8 Annuouda
7.8.1 Annuouda Company Details
7.8.2 Annuouda Business Overview
7.8.3 Annuouda Leukemia Molecular Diagnostics Introduction
7.8.4 Annuouda Revenue in Leukemia Molecular Diagnostics Business (2020-2025)
7.8.5 Annuouda Recent Development
7.9 Beijing Wantai
7.9.1 Beijing Wantai Company Details
7.9.2 Beijing Wantai Business Overview
7.9.3 Beijing Wantai Leukemia Molecular Diagnostics Introduction
7.9.4 Beijing Wantai Revenue in Leukemia Molecular Diagnostics Business (2020-2025)
7.9.5 Beijing Wantai Recent Development
7.10 Haixi Bio
7.10.1 Haixi Bio Company Details
7.10.2 Haixi Bio Business Overview
7.10.3 Haixi Bio Leukemia Molecular Diagnostics Introduction
7.10.4 Haixi Bio Revenue in Leukemia Molecular Diagnostics Business (2020-2025)
7.10.5 Haixi Bio Recent Development
7.11 Qiagen
7.11.1 Qiagen Company Details
7.11.2 Qiagen Business Overview
7.11.3 Qiagen Leukemia Molecular Diagnostics Introduction
7.11.4 Qiagen Revenue in Leukemia Molecular Diagnostics Business (2020-2025)
7.11.5 Qiagen Recent Development
7.12 Abbott
7.12.1 Abbott Company Details
7.12.2 Abbott Business Overview
7.12.3 Abbott Leukemia Molecular Diagnostics Introduction
7.12.4 Abbott Revenue in Leukemia Molecular Diagnostics Business (2020-2025)
7.12.5 Abbott Recent Development
7.13 Kanglu Biotechnology
7.13.1 Kanglu Biotechnology Company Details
7.13.2 Kanglu Biotechnology Business Overview
7.13.3 Kanglu Biotechnology Leukemia Molecular Diagnostics Introduction
7.13.4 Kanglu Biotechnology Revenue in Leukemia Molecular Diagnostics Business (2020-2025)
7.13.5 Kanglu Biotechnology Recent Development
7.14 Guangzhou Anbiping
7.14.1 Guangzhou Anbiping Company Details
7.14.2 Guangzhou Anbiping Business Overview
7.14.3 Guangzhou Anbiping Leukemia Molecular Diagnostics Introduction
7.14.4 Guangzhou Anbiping Revenue in Leukemia Molecular Diagnostics Business (2020-2025)
7.14.5 Guangzhou Anbiping Recent Development
8 Leukemia Molecular Diagnostics Market Dynamics
8.1 Leukemia Molecular Diagnostics Industry Trends
8.2 Leukemia Molecular Diagnostics Market Drivers
8.3 Leukemia Molecular Diagnostics Market Challenges
8.4 Leukemia Molecular Diagnostics Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Global Leukemia Molecular Diagnostics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Leukemia Molecular Diagnostics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Leukemia Molecular Diagnostics Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Leukemia Molecular Diagnostics Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Leukemia Molecular Diagnostics Revenue Share by Region (2020-2025)
Table 6. Global Leukemia Molecular Diagnostics Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Leukemia Molecular Diagnostics Revenue Share Forecast by Region (2026-2031)
Table 8. Global Leukemia Molecular Diagnostics Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Leukemia Molecular Diagnostics Revenue Market Share by Type (2020-2025)
Table 10. Global Leukemia Molecular Diagnostics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Leukemia Molecular Diagnostics Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Leukemia Molecular Diagnostics Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global Leukemia Molecular Diagnostics Revenue Market Share by Application (2020-2025)
Table 15. Global Leukemia Molecular Diagnostics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global Leukemia Molecular Diagnostics Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in Leukemia Molecular Diagnostics Application
Table 18. Global Leukemia Molecular Diagnostics Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Leukemia Molecular Diagnostics Market Share by Players (2020-2025)
Table 20. Global Top Leukemia Molecular Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Leukemia Molecular Diagnostics as of 2024)
Table 21. Ranking of Global Top Leukemia Molecular Diagnostics Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Leukemia Molecular Diagnostics Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Leukemia Molecular Diagnostics, Headquarters and Area Served
Table 24. Global Key Players of Leukemia Molecular Diagnostics, Product and Application
Table 25. Global Key Players of Leukemia Molecular Diagnostics, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Leukemia Molecular Diagnostics Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Leukemia Molecular Diagnostics Revenue Market Share by Company (2020-2025)
Table 29. North America Leukemia Molecular Diagnostics Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Leukemia Molecular Diagnostics Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe Leukemia Molecular Diagnostics Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Leukemia Molecular Diagnostics Revenue Market Share by Company (2020-2025)
Table 33. Europe Leukemia Molecular Diagnostics Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Leukemia Molecular Diagnostics Market Size by Application (2020-2025) & (US$ Million)
Table 35. China Leukemia Molecular Diagnostics Revenue by Company (2020-2025) & (US$ Million)
Table 36. China Leukemia Molecular Diagnostics Revenue Market Share by Company (2020-2025)
Table 37. China Leukemia Molecular Diagnostics Market Size by Type (2020-2025) & (US$ Million)
Table 38. China Leukemia Molecular Diagnostics Market Size by Application (2020-2025) & (US$ Million)
Table 39. Japan Leukemia Molecular Diagnostics Revenue by Company (2020-2025) & (US$ Million)
Table 40. Japan Leukemia Molecular Diagnostics Revenue Market Share by Company (2020-2025)
Table 41. Japan Leukemia Molecular Diagnostics Market Size by Type (2020-2025) & (US$ Million)
Table 42. Japan Leukemia Molecular Diagnostics Market Size by Application (2020-2025) & (US$ Million)
Table 43. Southeast Asia Leukemia Molecular Diagnostics Revenue by Company (2020-2025) & (US$ Million)
Table 44. Southeast Asia Leukemia Molecular Diagnostics Revenue Market Share by Company (2020-2025)
Table 45. Southeast Asia Leukemia Molecular Diagnostics Market Size by Type (2020-2025) & (US$ Million)
Table 46. Southeast Asia Leukemia Molecular Diagnostics Market Size by Application (2020-2025) & (US$ Million)
Table 47. India Leukemia Molecular Diagnostics Revenue by Company (2020-2025) & (US$ Million)
Table 48. India Leukemia Molecular Diagnostics Revenue Market Share by Company (2020-2025)
Table 49. India Leukemia Molecular Diagnostics Market Size by Type (2020-2025) & (US$ Million)
Table 50. India Leukemia Molecular Diagnostics Market Size by Application (2020-2025) & (US$ Million)
Table 51. Ruiang Gene Company Details
Table 52. Ruiang Gene Business Overview
Table 53. Ruiang Gene Leukemia Molecular Diagnostics Product
Table 54. Ruiang Gene Revenue in Leukemia Molecular Diagnostics Business (2020-2025) & (US$ Million)
Table 55. Ruiang Gene Recent Development
Table 56. Zhishan Bio Company Details
Table 57. Zhishan Bio Business Overview
Table 58. Zhishan Bio Leukemia Molecular Diagnostics Product
Table 59. Zhishan Bio Revenue in Leukemia Molecular Diagnostics Business (2020-2025) & (US$ Million)
Table 60. Zhishan Bio Recent Development
Table 61. Zhijiang Bio Company Details
Table 62. Zhijiang Bio Business Overview
Table 63. Zhijiang Bio Leukemia Molecular Diagnostics Product
Table 64. Zhijiang Bio Revenue in Leukemia Molecular Diagnostics Business (2020-2025) & (US$ Million)
Table 65. Zhijiang Bio Recent Development
Table 66. Jinpujia Medical Company Details
Table 67. Jinpujia Medical Business Overview
Table 68. Jinpujia Medical Leukemia Molecular Diagnostics Product
Table 69. Jinpujia Medical Revenue in Leukemia Molecular Diagnostics Business (2020-2025) & (US$ Million)
Table 70. Jinpujia Medical Recent Development
Table 71. Merle Bio Company Details
Table 72. Merle Bio Business Overview
Table 73. Merle Bio Leukemia Molecular Diagnostics Product
Table 74. Merle Bio Revenue in Leukemia Molecular Diagnostics Business (2020-2025) & (US$ Million)
Table 75. Merle Bio Recent Development
Table 76. Herui Gene Company Details
Table 77. Herui Gene Business Overview
Table 78. Herui Gene Leukemia Molecular Diagnostics Product
Table 79. Herui Gene Revenue in Leukemia Molecular Diagnostics Business (2020-2025) & (US$ Million)
Table 80. Herui Gene Recent Development
Table 81. Aicon Bio Company Details
Table 82. Aicon Bio Business Overview
Table 83. Aicon Bio Leukemia Molecular Diagnostics Product
Table 84. Aicon Bio Revenue in Leukemia Molecular Diagnostics Business (2020-2025) & (US$ Million)
Table 85. Aicon Bio Recent Development
Table 86. Annuouda Company Details
Table 87. Annuouda Business Overview
Table 88. Annuouda Leukemia Molecular Diagnostics Product
Table 89. Annuouda Revenue in Leukemia Molecular Diagnostics Business (2020-2025) & (US$ Million)
Table 90. Annuouda Recent Development
Table 91. Beijing Wantai Company Details
Table 92. Beijing Wantai Business Overview
Table 93. Beijing Wantai Leukemia Molecular Diagnostics Product
Table 94. Beijing Wantai Revenue in Leukemia Molecular Diagnostics Business (2020-2025) & (US$ Million)
Table 95. Beijing Wantai Recent Development
Table 96. Haixi Bio Company Details
Table 97. Haixi Bio Business Overview
Table 98. Haixi Bio Leukemia Molecular Diagnostics Product
Table 99. Haixi Bio Revenue in Leukemia Molecular Diagnostics Business (2020-2025) & (US$ Million)
Table 100. Haixi Bio Recent Development
Table 101. Qiagen Company Details
Table 102. Qiagen Business Overview
Table 103. Qiagen Leukemia Molecular Diagnostics Product
Table 104. Qiagen Revenue in Leukemia Molecular Diagnostics Business (2020-2025) & (US$ Million)
Table 105. Qiagen Recent Development
Table 106. Abbott Company Details
Table 107. Abbott Business Overview
Table 108. Abbott Leukemia Molecular Diagnostics Product
Table 109. Abbott Revenue in Leukemia Molecular Diagnostics Business (2020-2025) & (US$ Million)
Table 110. Abbott Recent Development
Table 111. Kanglu Biotechnology Company Details
Table 112. Kanglu Biotechnology Business Overview
Table 113. Kanglu Biotechnology Leukemia Molecular Diagnostics Product
Table 114. Kanglu Biotechnology Revenue in Leukemia Molecular Diagnostics Business (2020-2025) & (US$ Million)
Table 115. Kanglu Biotechnology Recent Development
Table 116. Guangzhou Anbiping Company Details
Table 117. Guangzhou Anbiping Business Overview
Table 118. Guangzhou Anbiping Leukemia Molecular Diagnostics Product
Table 119. Guangzhou Anbiping Revenue in Leukemia Molecular Diagnostics Business (2020-2025) & (US$ Million)
Table 120. Guangzhou Anbiping Recent Development
Table 121. Leukemia Molecular Diagnostics Market Trends
Table 122. Leukemia Molecular Diagnostics Market Drivers
Table 123. Leukemia Molecular Diagnostics Market Challenges
Table 124. Leukemia Molecular Diagnostics Market Restraints
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
List of Figures
Figure 1. Leukemia Molecular Diagnostics Product Picture
Figure 2. Global Leukemia Molecular Diagnostics Market Share by Type: 2024 VS 2031
Figure 3. PCR Features
Figure 4. FISH Features
Figure 5. DNA Sequencing Features
Figure 6. Gene Chip Features
Figure 7. Global Leukemia Molecular Diagnostics Market Share by Application: 2024 VS 2031
Figure 8. Clinical Diagnosis
Figure 9. Drug Screening
Figure 10. Research
Figure 11. Leukemia Molecular Diagnostics Report Years Considered
Figure 12. Global Leukemia Molecular Diagnostics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Leukemia Molecular Diagnostics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Leukemia Molecular Diagnostics Revenue Market Share by Region: 2020 VS 2024
Figure 15. North America Leukemia Molecular Diagnostics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. Europe Leukemia Molecular Diagnostics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 17. China Leukemia Molecular Diagnostics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. Japan Leukemia Molecular Diagnostics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 19. Southeast Asia Leukemia Molecular Diagnostics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. India Leukemia Molecular Diagnostics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 21. Central & South America Leukemia Molecular Diagnostics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 22. Global Leukemia Molecular Diagnostics Market Share by Players in 2024
Figure 23. Global Top Leukemia Molecular Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Leukemia Molecular Diagnostics as of 2024)
Figure 24. The Top 10 and 5 Players Market Share by Leukemia Molecular Diagnostics Revenue in 2024
Figure 25. North America Leukemia Molecular Diagnostics Market Share by Type (2020-2025)
Figure 26. North America Leukemia Molecular Diagnostics Market Share by Application (2020-2025)
Figure 27. Europe Leukemia Molecular Diagnostics Market Share by Type (2020-2025)
Figure 28. Europe Leukemia Molecular Diagnostics Market Share by Application (2020-2025)
Figure 29. China Leukemia Molecular Diagnostics Market Share by Type (2020-2025)
Figure 30. China Leukemia Molecular Diagnostics Market Share by Application (2020-2025)
Figure 31. Japan Leukemia Molecular Diagnostics Market Share by Type (2020-2025)
Figure 32. Japan Leukemia Molecular Diagnostics Market Share by Application (2020-2025)
Figure 33. Southeast Asia Leukemia Molecular Diagnostics Market Share by Type (2020-2025)
Figure 34. Southeast Asia Leukemia Molecular Diagnostics Market Share by Application (2020-2025)
Figure 35. India Leukemia Molecular Diagnostics Market Share by Type (2020-2025)
Figure 36. India Leukemia Molecular Diagnostics Market Share by Application (2020-2025)
Figure 37. Ruiang Gene Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2020-2025)
Figure 38. Zhishan Bio Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2020-2025)
Figure 39. Zhijiang Bio Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2020-2025)
Figure 40. Jinpujia Medical Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2020-2025)
Figure 41. Merle Bio Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2020-2025)
Figure 42. Herui Gene Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2020-2025)
Figure 43. Aicon Bio Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2020-2025)
Figure 44. Annuouda Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2020-2025)
Figure 45. Beijing Wantai Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2020-2025)
Figure 46. Haixi Bio Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2020-2025)
Figure 47. Qiagen Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2020-2025)
Figure 48. Abbott Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2020-2025)
Figure 49. Kanglu Biotechnology Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2020-2025)
Figure 50. Guangzhou Anbiping Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2020-2025)
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed
